Evaluation of efficacy of low molecular weight heparin calcium for acute ischemic stroke with lower extremity deep venous thrombosis
Objective To explore the effect of low molecular weight heparin calcium for acute ischemic stroke with lower extremity deep venous thrombosis and evaluate its safety.Methods 50 patients with acute ischemic stroke and lower extremity deep venous thrombosis were divided into a control group and a treatment group according to random numerical table,with 25 cases in each group.The control group was given conventional therapy,and the treatment group was given conventional therapy combined with low molecular weight heparin calcium therapy.Both groups were compared in terms of clinical efficacy,clinical prognosis[National Institutes of Health Stroke Scale(NIHSS)score],the risk of venous thromboembolism(VTE)(Padua score),and the incidence of adverse reactions(thrombocytopenia,skin changes at the injection site,abnormal liver and kidney function,and bleeding).Results The total effective rate of the treatment group was 80%,while the total effective rate of the control group was 52%;the treatment group was higher than the control group,and the difference was statistically significant(P<0.05).After treatment,the NIHSS score of the treatment group was(7.08±1.29)points,which was lower than(11.24±1.20)points of the control group,and the difference was statistically significant(P<0.05).After treatment,Padua score of the treatment group was(2.28±1.02)points,which was lower than(4.40±1.35)points of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 28%(7/25)in the treatment group and 32%(8/25)in the control group,and there was no statistical significance between the two groups(P>0.05).Conclusion Low molecular weight heparin calcium can promote the recovery of limb function and reduce the occurrence of adverse reactions in patients with acute ischemic stroke complicated with lower extremity deep venous thrombosis,and achieve ideal results in the treatment of acute ischemic stroke complicated with lower extremity deep venous thrombosis.
万方数据
维普
